Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Wong Mito Lab, |
RCV000758288 | SCV000886942 | uncertain significance | Progressive sclerosing poliodystrophy | 2018-10-01 | criteria provided, single submitter | clinical testing | The NM_002693.2:c.1639G>T (NP_002684.1:p.Ala547Ser) [GRCH38: NC_000015.10:g.89326685C>A] variant in POLG gene is interpretated to be a Uncertain Significance based on ACMG guidelines (PMID: 25741868). This variant meets the following evidence codes reported in the ACMG-guideline. BP4:Computational evidence/predictors indicate no impact on the POLG structure, function, or protein-protein interaction. Based on the evidence criteria codes applied, the variant is suggested to be Uncertain Significance. |
Labcorp Genetics |
RCV000758288 | SCV000958612 | uncertain significance | Progressive sclerosing poliodystrophy | 2021-08-31 | criteria provided, single submitter | clinical testing | This sequence change replaces alanine with serine at codon 547 of the POLG protein (p.Ala547Ser). The alanine residue is weakly conserved and there is a moderate physicochemical difference between alanine and serine. This variant is present in population databases (rs779353857, ExAC 0.002%). This variant has not been reported in the literature in individuals affected with POLG-related conditions. Algorithms developed to predict the effect of missense changes on protein structure and function (SIFT, PolyPhen-2, Align-GVGD) all suggest that this variant is likely to be tolerated. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Mayo Clinic Laboratories, |
RCV004792430 | SCV005411134 | uncertain significance | not provided | 2023-06-09 | criteria provided, single submitter | clinical testing | BP4, PM2_moderate |